middle.news
Saluda Medical Beats FY26 Revenue Guidance with 28% Growth and FDA Approval
8:31am on Wednesday 29th of July, 2026 AEST
•
Healthcare
Read Story
Saluda Medical Beats FY26 Revenue Guidance with 28% Growth and FDA Approval
8:31am on Wednesday 29th of July, 2026 AEST
Key Points
FY26 revenue hits US$90.2 million, 28% year-on-year growth
Q4 global revenue jumps 43%, US up 45%, international up 39%
FDA approves CAP24 paddle lead, expanding US surgical market access
US implanted patients grow 50%, active physicians up 22%
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Saluda Medical, (ASX:SLD)
OPEN ARTICLE